1.

LM患者的基本情况

Characteristics of patients with LM

No.	Sex	Age at LM	Histology	Initial stage	Smoking	Median time from cancer diagnosis to LM (mon)	Time from the start of TKI to LM (mon)	GCOG at LM	CSF cytologic testing	Brain and spinal MRI	CSF NGS	BM	Baseline mutation	TKI before LM	TKI after LM	WBRT
LM: leptomeningeal metastases; ECOG: Eastern Clinical Oncology Group; MRI: magnetic resonance imaging; BM: brain metastases; TKI: tyrosine kinase inhibitor; WBRT: whole brain radiation therapy; F: female; M: male; AD: adenocarcinoma; N: negative; P: positive; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; ROS1: ROS proto-oncogene 1, receptor tyrosine kinase.
1	F	62	AD	IV	No	25	25	2	P	P	P	N	EGFR	Icotinib	Osimertinib	N
2	M	46	AD	II	Yes	63	10	1	P	N	P	N	EGFR	Gefitinib	Osimertinib	N
3	M	50	AD	II	Yes	31	6	2	N	P	P	N	EGFR	Icotinib	Osimertinib	N
4	F	38	AD	IV	No	13	7	2	P	N	P	N	EGFR	Gefitinib	Osimertinib	N
5	M	56	AD	IV	Yes	35	34	1	N	P	P	Y	EGFR	Gefitinib, Erlotinib	Osimertinib	N
6	F	58	AD	IV	No	29	28	2	P	P	P	N	EGFR	Gefitinib	Osimertinib	N
7	M	59	AD	III	Yes	28	23	3	P	P	P	N	EGFR	Osimertinib	Gefitinib	N
8	F	51	AD	IV	Yes	30	30	2	P	P	P	N	EGFR	Gefitinib, Crizotinib	Osimertinib	N
9	F	39	AD	III	No	36	21	2	P	P	P	N	EGFR	Icotinib	Erlotinib, Osimertinib	N
10	M	54	AD	III	Yes	31	23	1	P	P	P	Y	EGFR	Icotinib, Erlotinib	Osimertinib	Y
11	M	48	AD	III	Yes	12	9	2	P	P	P	Y	EGFR	Gefitinib, Erlotinib	Osimertinib, Crizotinib	Y
12	F	62	AD	IV	No	8	8	2	P	P	P	Y	ALK	Crizotinib, Brigatinib	Alectinib, Lorlatinib	Y
13	F	44	AD	IV	No	11	10	1	P	P	P	Y	ALK	Crizotinib, Alectinib	Lorlatinib	N
14	F	48	AD	IV	No	29	17	2	P	N	P	N	ALK	Lorlatinib	Alectinib	N
15	M	33	AD	IV	Yes	10	9	1	P	P	P	N	ALK	Crizotinib	Lorlatinib	N
16	F	33	AD	III	No	15	11	2	N	P	P	N	ALK	Crizotinib	Alectinib	N
17	M	46	AD	III	Yes	9	5	3	P	P	P	Y	ALK	Crizotinib, Brigatinib	Lorlatinib, Alectinib	Y
18	M	39	AD	IV	Yes	39	19	3	P	P	P	N	ROS1	Crizotinib Cabozantinib	Lorlatinib	N